Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“Late-breaking abstracts related to ADCs at ESMO25 (LBA16 and LBA21 have not yet been released).
More than 10% of LBAs are on ADCs!”
More posts featuring ESMO2025 on OncoDaily.